Heterobifunctional degraders targeting BCR-Abl, BTK, CDK9, and DAPK1 offer a strategy to bypass kinase inhibitor resistance. Explore ligand design principles. Introduction Targeted protein degradation has emerged as one of the most compellingRead More…